Rossari Biotech Limited (ROSSARI) — Financial Results(2 announcements)

Investor Takeaways

Overall Tone: Neutral based on the numbers only.

Key Financial Highlights

What Changed

Rossari Biotech reported consolidated revenue of Rs. 697.2 crore for Q1 FY27, up 28% year-on-year, driven by growth across HPPC, TSC, and AHN segments. EBITDA rose 19% to Rs. 80.6 crore, reflecting improved operational efficiency. Profit after tax increased 4% to Rs. 35.1 crore, indicating margin pressure as profitability did not scale proportionally with revenue. The company achieved record quarterly revenue and EBITDA, supported by expansion into Southeast Asia through a new Thailand facility and the sale of its Andheri office as part of non-core asset monetisation. The forward-looking statements in the release noted risks related to market and regulatory conditions, though no specific operational or financial risks were detailed. The company emphasized disciplined execution, innovation, and profitable growth for FY27, underpinned by a healthy balance sheet.

Peer Comparison

Rossari Biotech trades at a significantly lower P/E multiple compared to its peers, suggesting relatively lower valuation expectations, though peer profitability metrics are not directly comparable due to missing ROE and ROCE data.

Risks & Concerns

Quarterly Trend

In Q1 FY27, revenue growth accelerated to 28% YoY from 9% in Q4FY24, while OPM declined to 11.56% from over 13% in the prior four quarters, indicating rising cost pressures despite top-line expansion. Net profit growth slowed to 4% YoY, lagging revenue growth, which suggests margin compression. The trend shows improving scale but increasing sensitivity to operational and expansion-related costs.

About Rossari Biotech Limited (ROSSARI)

Chemicals · Chemicals & Petrochemicals · Listed on NSE

View full ROSSARI stock details →